Skip to main content

Advertisement

SpringerLink
Log in

Pharmacokinetic-Pharmacodynamic Relationships of H1-Antihistamines

  • Review Article
  • Pharmacokinetic-Pharmacodynamic Relationships
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Histamine H1-receptor antagonists are reversible, competitive inhibitors of the actions of histamine, a critical mediator in the pathophysiology of the allergic response. This review is mainly devoted to second generation antihistamines that possess a low sedation potential compared with first generation compounds. The pharmacokinetic and pharmacodynamic data of 10 compounds have been updated. Some values are lacking for drugs under development, but also for older antihistamines. Thereafter, pharmacokinetic-pharmacodynamic relationships are reported from published or original documents.

A linear pharmacokinetic-pharmacodynamic relationship has been found for acrivastine, astemizole, cetirizine, ebastine and terfenadine, whereas nonlinear relationships have been calculated for ebastine (in the dog), levocabastine, mizolastine, noberastine and terfenadine. It must be concluded that this type of approach for therapeutic optimisation is very fruitful and may enable large numbers of clinical studies to be avoided.

Trends for the future include: (i) in vitro binding studies with the human H1-receptor obtained by molecular biology; (ii) the characterisation of the cytochromes P450 responsible for the biotransformation of antihistamines; (iii) the calculation of the pharmacokinetic-pharmacodynamic relationship in healthy individuals; and (iv) prospective effect-controlled clinical studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Green JP, Prell GD, Khandelwal JK, et al. Aspects of histamine metabolism. Agents Actions 1987; 22: 1–15

    Article  PubMed  CAS  Google Scholar 

  2. Green JP. Histamine receptors. In: Meitzer HY, editor. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987: 273–9

    Google Scholar 

  3. Rimmer SJ, Church MK. The pharmacology and mechanisms of action of histamine H1-antagonists. Clin Exp Allergy 1990; 20 Suppl. 2: 3–17

    Article  PubMed  Google Scholar 

  4. Advenier C, Queille-Roussel C. Rational use of antihistamines in allergic dermatological conditions. Drugs 1989; 38: 634–44

    Article  PubMed  CAS  Google Scholar 

  5. Brogden RN, McTavish D. Acrivastine: a review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. Drugs 1991; 41: 927–40

    Article  PubMed  CAS  Google Scholar 

  6. Chang SY, Nelson FR, Findlay JWA, et al. Quantitative gas chromatographic-mass spectrometric analysis of acrivastine and a metabolite in human plasma. J Chromatogr 1989; 497: 288–95

    Article  PubMed  CAS  Google Scholar 

  7. Liao SHT, Fleck RJ, Blum MR, et al. Clinical pharmacokinetics and safety of acrivastine (AV) with pseudoephedrine (PE) in geriatric volunteers [abstract]. J Pharm Sci 1987; 76: S113

    Google Scholar 

  8. Richards DM, Brogden RN, Heel RC, et al. Astemizole: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1984; 28: 38–61

    Article  PubMed  CAS  Google Scholar 

  9. Heykants J, Van Peer A, Woestenborghs R, et al. Dose-proportionality, bioavailability, and steady-state kinetics of astemizole in man. Drug Dev Res 1986; 8: 71–8

    Article  CAS  Google Scholar 

  10. Janssens MM-L, Caers I. Onset of action of astemizole. Int J Clin Pharm Res 1991; 11: 219–29

    CAS  Google Scholar 

  11. McTavish D, Sorkin EM. Azelastine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1989; 38: 778–800

    Article  PubMed  CAS  Google Scholar 

  12. Kemp JP, Meitzer EO, Orgel HA, et al. A dose-response study of the bronchodilator action of azelastine in asthma. J Allergy Clin Immunol 1987; 79: 893–9

    Article  PubMed  CAS  Google Scholar 

  13. Weliky I, Howard JR, Wichmann JK. Absolute bioavailability (AB) and pharmacokinetics (PK) of azelastine (AZ) [abstract]. Pharm Res 1990; 7: S247

    Article  Google Scholar 

  14. Thomas KE, Ollier S, Ferguson H, et al. The effect of intranasal azelastine, Rhinolast, on nasal airways obstruction and sneezing following provocation testing with histamine and allergen. Clin Exp Allergy 1992; 22: 642–7

    Article  PubMed  CAS  Google Scholar 

  15. Campoli-Richards DM, Buckley MM-T, Fitton A. Cetirizine: a review of its pharmacological properties and clinical potential in allergic rhinitis, pollen-induced asthma, and chronic urticaria. Drugs 1990; 40: 762–81

    Article  PubMed  CAS  Google Scholar 

  16. Spencer CM, Faulds D, Peters DH. Cetirizine: a reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs 1993; 46: 1055–80

    Article  PubMed  CAS  Google Scholar 

  17. Gengo FM, Dabronzo J, Yurchak A, et al. The relative antihistaminic and psychomotor effects of hydroxyzine and cetirizine. Clin Pharmacol Ther 1987; 42: 265–72

    Article  PubMed  CAS  Google Scholar 

  18. Desager JP, Dab I, Horsmans Y, et al. A pharmacokinetic evaluation of the second-generation H1-receptor antagonist cetirizine in very young children. Clin Pharmacol Ther 1993; 53: 431–5

    Article  PubMed  CAS  Google Scholar 

  19. Spicak V, Klanova M, Hulhoven R, et al. Pharmacokinetics and pharmacodynamics of cetirizine in infants [abstract]. J All Clin Immunol 1995; 95 Suppl 1: 197

    Google Scholar 

  20. Pellegrin PL, Jacqmin PE, Van Bel P, et al. Mechanism of the renal clearance of cetirizine [abstract]. Eur J Drug Metab Pharmacokinet 1990; 15: S31

    Article  Google Scholar 

  21. Horsmans Y, Desager JP, Hulhoven R, et al. Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. J Clin Pharmacol 1993; 33: 929–32

    PubMed  CAS  Google Scholar 

  22. Simons FER, Watson WTA, Minuk GY, et al. Cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis. J Clin Pharmacol 1993; 33: 949–54

    PubMed  CAS  Google Scholar 

  23. Simons FER, Murray HE, Yi Z, et al. Cetirizine and hydroxyzine concentrations in human skin [abstract]. J Allergy Clin Immunol 1994; 93: 222

    Google Scholar 

  24. Vincent J, Liminana R, Meredith PA, et al. The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects. Br J Clin Pharmacol 1988; 26: 497–501

    Article  PubMed  CAS  Google Scholar 

  25. Yamaguchi T, Hashizume T, Matsuda M, et al. Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects. Arzneimittel Forschung 1994; 44: 59–64

    PubMed  CAS  Google Scholar 

  26. Simons FER, Watson WTA, Simons KJ. The pharmacokinetics and pharmacodynamics of the H1-antagonist ebastine in children [abstract]. J Allergy Clin Immunol 1993; 91: 258

    Google Scholar 

  27. Dechant KL, Goa KL. Levocabastine: a review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Drugs 1991; 41: 202–24

    Article  PubMed  CAS  Google Scholar 

  28. Clissold SP, Sorkin EM, Goa KL. Loratadine: a preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 1989; 37: 42–57

    Article  PubMed  CAS  Google Scholar 

  29. Haria M, Fitton A, Peters DH. Loratadine: a reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs 1994; 48: 617–37

    Article  PubMed  CAS  Google Scholar 

  30. Johnson R, Christensen J, Lin CC. Sensitive gas-liquid chromatographic method for the determination of loratadine and its major active metabolite, descarboethoxyloratadine, in human plasma using a nitrogen-phosphorus detector. J Chromatogr 1994; 657: 125–31

    Article  CAS  Google Scholar 

  31. Rosenzweig P, Thebault JJ, Caplain H, et al. Pharmacodynamics and pharmacokinetics of mizolastine (SL 85.0324), a new nonsedative H1 antihistamine. Ann Allergy 1992; 69: 135–9

    PubMed  CAS  Google Scholar 

  32. Hulot T, Bianchetti G, Ascalone V, et al. Absolute bioavailability and absorption kinetics of a new benzimidazole derivative: mizolastine, in healthy volunteers [abstract]. Poster presented at the Fifth European Congress of Biopharmaceutics and Pharmacokinetics; 1993 April 20–22; Brussels, Abstract 138

  33. Leysen JE, Gommeren W, Janssen PFM, et al. Comparative study of central and peripheral histamine-H1 receptor binding in vitro and ex vivo of non-sedating antihistamines and of noberastine, a new agent. Drug Dev Res 1991; 22: 165–78

    Article  CAS  Google Scholar 

  34. Heykants JJP, Snoeck E, Awouters F, et al. Antihistamines. In: van Boxtel CJ, Holford NHG, Danhof M, editors. The in vivo study of drug action. Amsterdam: Elsevier Science Publishers, 1992; 337–56

    Google Scholar 

  35. Sorkin EM, Heel RC. Terfenadine: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1985; 29: 34–56

    Article  PubMed  CAS  Google Scholar 

  36. McTavish D, Goa KL, Ferrill M. Terfenadine: an updated review of its pharmacological properties and therapeutic efficacy. Drugs 1990; 39: 552–74

    Article  PubMed  CAS  Google Scholar 

  37. Eller MG, Walker BJ, Westmark PA, et al. Pharmacokinetics of terfenadine in healthy elderly subjects. J Clin Pharmacol 1992; 32: 267–71

    PubMed  CAS  Google Scholar 

  38. Eller MG, Okerholm RA. Pharmacokinetics of terfenadine [abstract]. Pharm Res 1990; 7: S206

    Google Scholar 

  39. Simons KJ, Martin TJ, Watson WTA, et al. Pharmacokinetics and pharmacodynamics of terfenadine and chlorpheniramine in the elderly. J Allergy Clin Immunol 1990; 85: 540–7

    Article  PubMed  CAS  Google Scholar 

  40. Simons FER, Watson WTA, Simons KJ. The pharmacokinetics and pharmacodynamics of terfenadine in children. J Allergy Clin Immunol 1987; 80: 884–90

    Article  PubMed  CAS  Google Scholar 

  41. Murdoch RD, Youlten LJF, Williams AJ, et al. Plasma concentrations and urinary excretion of histamine after inhalation and subcutaneous injection of histamine. Br J Clin Pharmacol 1993; 35: 171–7

    Article  PubMed  CAS  Google Scholar 

  42. Rihoux J-P. H1-Antihistamines as broad-spectrum drugs for the treatment of various allergic disorders. In: Langer SZ, Church MK, Vargaftig BB, et al., editors. New developments in the therapy of allergic disorders and asthma. International Academy of Biomedical and Drug Research Basel: Karger, 1993; 6: 55–9

    Google Scholar 

  43. Townley RG, Okada C. Use of cetirizine to investigate non-H1 effects of second-generation antihistamines. Ann Allergy 1992; 68: 190–6

    PubMed  CAS  Google Scholar 

  44. Meitzer EO. Comparative safety of H1 antihistamines. Ann Allergy 1991; 67: 625–33

    Google Scholar 

  45. Sanders RL, Dockhorn RJ, Alderman JL, et al. Cardiac effects of acrivastine compared to terfenadine [abstract]. J Allergy Clin Immunol 1992; 89: 183

    Article  Google Scholar 

  46. Janssens MM-L. Astemizole: a nonsedating antihistamine with fast and sustained activity. Clin Rev Allergy 1993; 11: 35–63

    PubMed  CAS  Google Scholar 

  47. Laine K, Kivistö KT, Neuvonen PJ. The effect of activated charcoal on the absorption and elimination of astemizole. Hum Exp Toxicol 1994; 13: 502–5

    Article  PubMed  CAS  Google Scholar 

  48. Horak F, Jäger S, Toth J, et al. Azelastine in pollen-induced allergic rhinitis: a pharmacodynamic study of onset of action and efficacy. Drug Invest 1994; 7: 34–40

    Article  Google Scholar 

  49. Coulie PJ, Ghys L, Rihoux J-P. Inhibitory effects of orally or sublingually administered cetirizine on histamine-induced weals and flares and their correlation with cetirizine plasma concentrations. J Int Med Res 1991; 19: 174–9

    PubMed  CAS  Google Scholar 

  50. Rombaut NEI, Hindmarch I. Psychometric aspects of antihistamines: a review. Hum Psychopharmacol Clin Exp 1994; 9: 157–69

    Article  CAS  Google Scholar 

  51. Simons FER, Sussman GL, Simons KJ. Effect of the H2-antagonist Cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. J Allergy Clin Immunol. In press

  52. Wood-Baker R, Holgate ST. Dose-response relationship of the H1-histamine antagonist, ebastine, against histamine and methacholine-induced bronchoconstriction in patients with asthma. Agents Actions 1990; 30: 284–6

    Article  PubMed  CAS  Google Scholar 

  53. Hopes H, Meuret G-H, Ungethüm W, et al. Placebo controlled comparison of acute effects of ebastine and clemastine on performance and EEG. Eur J Clin Pharmacol 1992; 42: 55–9

    Article  PubMed  CAS  Google Scholar 

  54. Van Rooij J, Schoemaker HC, Bruno R, et al. Cimetidine does not influence the metabolism of the H1-receptor antagonist ebastine to its active metabolite carebastine. Br J Clin Pharmacol 1993; 35: 661–3

    Article  PubMed  Google Scholar 

  55. Rombaut N, Bhatti JZ, Curran S, et al. Effects of topical administration of levocabastine on psychomotor and cognitive function. Ann Allergy 1991; 67: 75–9

    PubMed  CAS  Google Scholar 

  56. Affrime MB, Lorber R, Danzig M, et al. Three month evaluation of electrocardiographic effects of loratadine in humans [abstract]. J Allergy Clin Immunol 1993; 91: 259

    Google Scholar 

  57. Van Peer A, Crabbé R, Woestenborghs R, et al. Ketoconazole inhibits loratadine metabolism in man [abstract]. Allergy 1993; 48 Suppl. 16: 34

    Google Scholar 

  58. Pechadre JC, Vernay D, Trolese JF, et al. Comparison of the central and peripheral effects of cetirizine and terfenadine. Eur J Clin Pharmacol 1988; 35: 255–9

    Article  PubMed  CAS  Google Scholar 

  59. Kivistö KT, Neuvonen PJ, Klotz U. Inhibition of terfenadine metabolism: pharmacokinetic and pharmacodynamic consequences. Clin Pharmacokinet 1994; 27: 1–5

    Article  PubMed  Google Scholar 

  60. Honig PK, Wortham DC, Hull R, et al. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 1993; 33: 1201–6

    PubMed  CAS  Google Scholar 

  61. Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981; 6: 429–53

    Article  PubMed  CAS  Google Scholar 

  62. Donnelly R, Meredith PA, Elliott HL. Pharmacokinetic-pharmacodynamic relationships of α-adrenoceptor antagonists. Clin Pharmacokinet 1989; 17: 264–74

    Article  PubMed  CAS  Google Scholar 

  63. Levy G, Ebling WF, Forrest A. Concentration- or effect-controlled clinical trials with sparse data. Clin Pharmacol Ther 1994; 56: 1–8

    Article  PubMed  CAS  Google Scholar 

  64. Cohen AF, Hamilton MJ, Liao SHT, et al. Pharmacodynamic and pharmacokinetics of BW 825C: a new antihistamine. Eur J Clin Pharmacol 1985; 28: 197–204

    Article  PubMed  CAS  Google Scholar 

  65. Howarth PH, Emanuel MB, Holgate ST. Astemizole, a potent histamine H1-receptor antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels. Br J Clin Pharmacol 1984; 18: 1–8

    Article  PubMed  CAS  Google Scholar 

  66. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513–8

    Article  PubMed  CAS  Google Scholar 

  67. Puigdemont A, Queralt M, Jansat JM, et al. Pharmacokinetic and pharmacodynamic studies of the histamine H1-receptor antagonist ebastine in dogs. J Pharm Pharmacol 1994; 46: 596–9

    Article  PubMed  CAS  Google Scholar 

  68. Simons FER. H1-receptor antagonists: comparative tolerability and safety. Drug Saf 1994; 10: 350–80

    Article  PubMed  CAS  Google Scholar 

  69. Corey JP. Advances in the pharmacotherapy of allergic rhinitis: second-generation H1-receptor antagonists. Otolaryngol Head Neck Surg 1993; 109: 584–92

    PubMed  CAS  Google Scholar 

  70. De Backer MD, Gommeren W, Moereels H, et al. Genomic cloning, heterologous expression and pharmacological characterization of a human histamine H1-receptor. Biochem Biophys Res Commun 1993; 197: 1601–8

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratoire de Pharmacotherapie, Universite Catholique de Louvain, Brussels, Belgium

    Jean-Pierre Desager & Yves Horsmans

Authors
  1. Jean-Pierre Desager
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yves Horsmans
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Desager, JP., Horsmans, Y. Pharmacokinetic-Pharmacodynamic Relationships of H1-Antihistamines. Clin. Pharmacokinet. 28, 419–432 (1995). https://doi.org/10.2165/00003088-199528050-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199528050-00006

Keywords

Search

Navigation